Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-18
2006-07-18
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S249000
Reexamination Certificate
active
07078409
ABSTRACT:
The present invention is directed to a compound having the structurewherein A is a 7–18 membered ring that comprises 0 to 6 heteroatoms selected from O, S, and N; R1is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-8alkyl, substituted or unsubstituted C2-8alkenyl, substituted or unsubstituted C2-8alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl; m is an integer from 0 to 3; X is selected from the group consisting of NR2, CHR3, O, or S; wherein R2and R3are each individually H or C1-8alkyl; R is selected from the group consisting of unsubstituted aryl, and substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl-(C1-3)alkyl, substituted or unsubstituted aryl-(C3-7)cycloalkyl, substituted or unsubstituted heteroaryl-(C1-3)alkyl, and substituted or unsubstituted heteroaryl-(C3-7)cycloalkyl; and pharmaceutically acceptable salts thereof; with the proviso that if A is a 7 or 8 membered ring, then R1is selected from the group consisting of other than H, C1–C4alkyl, (C1–C4alkoxy)C1–C4alkyl, C1–C4alkanoyl, C1–C4alkoxy or —S(O)x(C1–C4alkyl) wherein x is 0 to 2, and wherein said alkyl group and the alkyl moieties of said R1groups are optionally substituted by 1 to 3 halogens. The present invention is also directed to pharmaceutical compositions comprising the above compound, and methods of treating patients suffering from tyrosine kinase-mediated disorders using the above compound.
REFERENCES:
patent: 5250679 (1993-10-01), Blackburn et al.
patent: 5403836 (1995-04-01), Blackburn et al.
patent: 5457105 (1995-10-01), Barker
patent: 5569658 (1996-10-01), Barker
patent: 5616582 (1997-04-01), Barker
patent: 5654307 (1997-08-01), Bridges et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 6066638 (2000-05-01), Bereznak et al.
patent: 6265410 (2001-07-01), Bridges et al.
patent: 6335344 (2002-01-01), Schnur
patent: 1 044 969 (2000-10-01), None
patent: 2000-290262 (2000-10-01), None
patent: WO 95/19970 (1995-07-01), None
patent: WO 96/30347 (1996-10-01), None
patent: WO 97/13760 (1997-04-01), None
patent: WO 97/49688 (1997-12-01), None
patent: WO 99/55683 (1999-11-01), None
patent: WO 01/32155 (2001-05-01), None
patent: WO 01/34574 (2001-05-01), None
patent: WO 01/70255 (2001-09-01), None
patent: WO 02/05791 (2002-01-01), None
Chen Hang
Cheng Zhengzhuang
Davis Charles
Kamal Mehrnaz
Wang Yinxiang
Beta Pharma, Inc.
Galletta Elizabeth A.
Garabedian Todd E.
Truong Tamthom N.
Wiggin and Dana LLP
LandOfFree
Fused quinazoline derivatives useful as tyrosine kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused quinazoline derivatives useful as tyrosine kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused quinazoline derivatives useful as tyrosine kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3547140